Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the Advancement of Novel Non-Opioid Pain Therapeutics

Bozeman, MT – SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announces the addition of some of the world’s leading medical and scientific experts in the treatment of acute and chronic pain to its Scientific Advisory Board.  

“Our research and development team has made tremendous progress with our portfolio of novel, small molecule Naᵥ1.7 inhibitors for the treatment of acute and chronic pain,” said Stan Abel, President and Chief Executive Officer of SiteOne Therapeutics.  “Having access to such an outstanding team of scientific advisors is critical as we accelerate the development of these promising drug candidates.” 

“SiteOne’s therapeutic candidates exhibit impressive potency and selectivity for NaV1.7, and engage the target in a way that differentiates them from other inhibitors of Nav1.7. Their compounds show great promise as novel, non-opioid solutions for the treatment of pain” added Dr. Stephan G. Waxman, MD, PhD, Chair of the SiteOne Therapeutics Scientific Advisory Board.  “We look forward to working with the SiteOne team as they advance these drug candidates to clinical trials.”

Members of the SiteOne Therapeutics Scientific Advisory Board:

Stephen G. Waxman, MD, PhD (Chair)

  • Bridget Marie Flaherty Professor of Neurology, Neuroscience, and Pharmacology;
  • Chairman, Department of Neurology (1986-2009), Yale University School of Medicine;
  • Director, Center for Neuroscience & Regeneration Research, Yale University School of Medicine

Martin S. Angst, MD

  • Professor, Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine;  
  • Founder/Director Human Experimental Pain Laboratory (1996-2011), Department of Anesthesia Stanford University School of Medicine;
  • Leader Perioperative Immune Health Initiative, Department of Anesthesia Stanford University School of Medicine;

Anthony Ford, PhD

  • Neuroscientist and drug discovery entrepreneur
  • Founder / Chief Scientific Officer Afferent Pharmaceuticals (acquired by Merck 2016)
  • Former Vice President, Research, Head of Neuroscience, Roche Palo Alto

Frank Porreca, PhD

  • Professor and Associate Department Head, Pharmacology, University of Arizona
  • Professor, Anesthesiology, Cancer Biology – GIDP, Neuroscience – GIDP, Pharmacology

Michael C. Rowbotham, M.D.

  • Scientific Director, California Pacific Medical Center Research Institute
  • Adjunct Professor of Anesthesia, UCSF
  • Attending Physician, UCSF Pain Management Center
  • Emeritus Professor of Clinical Neurology, UCSF

In January 2017, SiteOne announced the closing of a research and development agreement with Amgen, a collaboration focused on combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.  At the same time, SiteOne announced the closing of a $15 million series B round of financing, led by Amgen and joined by founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC, and Z Investments.   

About SiteOne Therapeutics

SiteOne Therapeutics is headquartered in Bozeman, Montana with a research team based in South San Francisco, California.  SiteOne is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Given the critical role Naᵥ1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.  For more information, visit SiteOne’s Web site at www.site1therapeutics.com

#  #  #

SiteOne Therapeutics Announces Abstract Presentation at the Association for Research in Vision and Opthamology

BOZEMAN, Montana - SiteOne Therapeutics, Inc., today announced a presentation at the Association for Research in Vision and Opthalmology (ARVO) meeting in Honolulu, Hawaii, April 29 to May 3, 2018. 

The abstract will present preclinical research using SiteOne’s novel sodium ion channel blockers showing corneal anesthesia, penetration into the ocular structures, and excellent tolerability after topical administration.  The study was conducted to inform development of a novel drug candidate to treat ocular pain associated with dry eye syndrome.

Accepted ARVO abstract is listed below:

Delwig, A. et al, “Evaluation of Selective NaV 1.7 Inhibitors for the Treatment of Ocular Pain” Abstract # 2908312, Poster Presentation.

About Ocular Pain Associated with Dry Eye Syndrome

Dry eye syndrome is a clinical diagnosis that encompasses a broad range of distinct conditions with unique etiologies that share signs and symptoms, the most common of which are sensations of burning, stinging, itching or grittiness in the eyes. The objective of our program is to develop a topical ophthalmic analgesic to safely and effectively treat ocular discomfort associated with the diagnosis of dry eye. This product would also be useful for treating other types of ocular pain, such as post-surgical pain and pain associated with acute corneal injuries or abrasions.

Existing therapeutics for dry eye include topical cyclosporine (Restasis) and lifitegrast (Xiidra). Both drugs address the inflammatory component of the disease by inhibiting activation of T-cells, however signs and symptoms of dry eye frequently persist.

The objective of our program is to advance a topical ophthalmic analgesic that reduces ocular discomfort associated with dry eye by targeting a voltage-gated sodium channel in the cornea, NaV1.7, and reducing corneal pain. Our product has the potential to be broadly effective in the ~30 million Americans suffering from dry eye regardless of the etiology because it addresses the discomfort rather than the heterogeneous physiologic cause. The analgesic would complement therapeutics that reduce inflammation or improve tear film, allowing the patient to be comfortable over weeks to months required for these therapies take effect. It would also be a useful treatment for postoperative pain following certain surgical procedure and acute ocular injuries, such as corneal abrasion.

About SiteOne Therapeutics, Inc.

SiteOne Therapeutics is a biotechnology company headquartered in Bozeman, Montana with a research laboratory in the South San Francisco, California.  Since its inception, SiteOne has been dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Given the urgent need for new, non-opioid solutions for managing pain, SiteOne is focused on advancing its lead product candidates for multiple therapeutic applications.

U.S. Department of Defense Awards Grant to SiteOne Therapeutics, Supporting Research and Development of Selective Small Molecule NaV1.7 Inhibitors as Acute and Chronic Pain Therapeutics

$1 Million Research Grant Helps Advance Existing Research and Development Partnership with Amgen

BOZEMAN, MT – The U.S. Dept. of Defense is supporting SiteOne Therapeutics in the effort to develop the company’s proprietary, highly selective small molecule Naᵥ1.7 inhibitors for the treatment of acute and chronic pain. 

In an announcement today, SiteOne Therapeutics Co-Founder and Vice President of Research, John Mulcahy, said “The validation and confidence of officials of the U.S. Department of Defense is exceptionally welcome.  There is a critical need for non-opioid therapeutics that treat acute and chronic pain effectively, allowing for less reliance on opioids, and reducing the side effects and addiction potential associated with them.  We are committed to advancing our research and development programs focused on Naᵥ1.7 and are inspired by the confidence of the many people and entities who support our approach.”

In January 2017, Stan Abel, Chief Executive Officer and President of SiteOne Therapeutics announced the closing of a research and development agreement with Amgen, a collaboration focused on combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.  At the same time, Abel announced that SiteOne had closed a $15 million series B round of financing, led by Amgen and joined by founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC, and Z Investments.

About SiteOne Therapeutics

SiteOne Therapeutics was founded with technology licensed from Stanford University. The company has advanced this science with support from its founding investors as well as from the National Institutes of Health (NIH) which contributed more than $3 million in Small Business Innovation Research (SBIR) grant funding.

SiteOne Therapeutics is headquartered in Bozeman, Montana with a research team based in the San Francisco, California area.  Since its inception, SiteOne has been dedicated to developing novel pain therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Given the critical role Naᵥ1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products for the treatment of moderate to severe pain.

DOD REQUIRED INFORMATION INCLUDED IN THIS PUBLIC ANNOUNCEMENT

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.  This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Broad Agency Announcement under Award No. W81XWH-17-1-0672. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.  In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture.  In the conduct of research utilizing recombinant DNA, the investigator adhered to NIH Guidelines for research involving recombinant DNA molecules.  In the conduct of research involving hazardous organisms or toxins, the investigator adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.                               

SiteOne Therapeutics Appoints Debra Odink, Ph.D., As Chief Development Officer as the Company Advances Novel Pain Drug Candidates

Bozeman, Montana – SiteOne Therapeutics announced today the appointment of Debra Odink, Ph.D. as Chief Development Officer, leading the effort to advance the company’s innovative small-molecule Naᵥ1.7-based therapeutic candidates for acute and chronic pain. 

“Dr. Odink has a demonstrated track record of successfully leading the development of multiple drug candidates in a variety of therapeutic areas.” said Stan Abel, President and Chief Executive Officer, SiteOne Therapeutics.  “Her experience will significantly strengthen our team of exceptional scientists to accelerate the development of our novel Nav1.7 product candidates.”

Prior to joining SiteOne, Dr. Odink most recently served as Senior Vice President of Technical Operations at Eiger BioPharmaceuticals, Inc., where she was responsible for the manufacturing operations for multiple programs.  Prior to this she served as Chief Technical Officer and Senior Vice President at Anthera Pharmaceuticals responsible for non-clinical, clinical and manufacturing operations.  Earlier in her career Dr. Odink was Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and served in the development organization for several years at Roche.

“Having worked with some of the world’s largest biopharmaceutical developers and with innovative start-up companies, it is clear to me that SiteOne Therapeutics has the talent, scientific acumen and commitment to improve the lives of patients,” said Dr. Odink.  “Given the opioid crisis in the United States and the lack of safe and effective alternatives for managing pain, I am excited to join the SiteOne team and to rapidly advance our drug candidates through preclinical and clinical evaluation.” 

In January of 2017, SiteOne Therapeutics announced its research and development agreement with Amgen, combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.  As part of its partnership with Amgen, SiteOne closed its $15 million series B round of financing, led by Amgen and joined by founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC, and Z Investments.

SiteOne was founded with technology licensed from Stanford University. The company has advanced this science with support from its founding investors as well as from the National Institutes of Health (NIH) which contributed more than $3 million in Small Business Innovation Research (SBIR) grant funding.

About SiteOne Therapeutics

SiteOne Therapeutics is headquartered in Bozeman, Montana with a research team based in South San Francisco, California.  Since its inception, SiteOne has been dedicated to developing novel pain therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Given the critical role Naᵥ1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products for the treatment of moderate to severe pain.

For more information, visit SiteOne’s Web site at www.site1therapeutics.com

#  #  #

SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of Naᵥ1.7 for Acute and Chronic Pain

SiteOne Announces the Concurrent Closing of its $15 Million Series B Round of Financing

Bozeman, Montana – SiteOne Therapeutics announced today the signing of a new research and development agreement with Amgen combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.

Read More